Michael Ciesielski

Michael Ciesielski

Company: MimiVax

Job title: CEO


Positive Clinical Updates on Vaccine-Based Approaches; Uncovering their Potential in Combination Therapy 8:45 am

SurVaxM – a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine targeting surviving Phase IIa study of surVaxM plus adjuvant temozolomide for newly diagnosed glioblastomaRead more

day: Conference Day 1

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.